Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study.
COVID-19
Immunosuppression
Lung
Omicron
Transplantation
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
07
07
2022
accepted:
25
08
2022
medline:
25
5
2023
pubmed:
10
9
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains unknown. The aim of the study was to assess outcome and associated factors in lung transplant recipients in a German-wide multicenter approach. All affected individuals from January 1st to March 20th, 2022 from 8 German centers during the Omicron wave were collected. Baseline characteristics and antiviral measures were associated with outcome. Of 218 patients with PCR-proven SARS-CoV-2 infection 166 patients (76%) received any early (< 7 days) antiviral therapy median 2 (interquartile range 1-4) days after symptom onset. Most patients received sotrovimab (57%), followed by remdesivir (21%) and molnupiravir (21%). An early combination therapy was applied in 45 patients (21%). Thirty-four patients (16%) developed a severe or critical disease severity according to the WHO scale. In total, 14 patients (6.4%) died subsequently associated with COVID-19. Neither vaccination and antibody status, nor applied treatments were associated with outcome. Only age and glomerular filtration rate < 30 ml/min/1.73m COVID-19 due to Omicron remains an important threat for lung transplant recipients. In particular, elderly patients and patients with impaired kidney function are at risk for worse outcome. Prophylaxis and therapy in highly immunocompromised individuals need further improvement.
Identifiants
pubmed: 36083405
doi: 10.1007/s15010-022-01914-8
pii: 10.1007/s15010-022-01914-8
pmc: PMC9461411
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
749-757Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2022 Apr 5;327(13):1236-1246
pubmed: 35285853
N Engl J Med. 2022 Apr 14;386(15):1475-1477
pubmed: 35263535
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Ann Intern Med. 2022 Jun;175(6):831-837
pubmed: 35286147
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
J Heart Lung Transplant. 2019 May;38(5):493-503
pubmed: 30962148
Am J Transplant. 2020 Nov;20(11):3072-3080
pubmed: 32881315
Am J Transplant. 2021 May;21(5):1825-1837
pubmed: 33098200
Eur Respir J. 2022 Jul 21;60(1):
pubmed: 35618274
Transplantation. 2021 Jun 1;105(6):1365-1371
pubmed: 33988341
Am J Transplant. 2022 Aug;22(8):2083-2088
pubmed: 35278260
Am J Transplant. 2022 Jan;22(1):279-288
pubmed: 34514710
J Heart Lung Transplant. 2021 Aug;40(8):754-758
pubmed: 34120839
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Transplantation. 2021 Nov 1;105(11):e263-e264
pubmed: 34310530
PLoS One. 2021 Oct 6;16(10):e0257807
pubmed: 34613977
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Am J Transplant. 2020 Oct;20(10):2928-2932
pubmed: 32400084
Transplantation. 2022 Mar 1;106(3):e183-e184
pubmed: 34856599
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Nature. 2022 Jul;607(7917):119-127
pubmed: 35576972